Table 1.
Pertinent Studies with Immunotherapy, Chemotherapy, and/or Radiation in Melanoma Brain Metastases
| Study | Regimen | Radiation Therapy | Phase | No. Patients | Overall Intracranial Response Rate % | Progression-Free Survival or Median Time to Progression | Median Overall Survival Months |
|---|---|---|---|---|---|---|---|
| BREAK-MB Long et al. 2012[5], [32] |
Dabrafenib | None | II | Cohort A (no prior treatment): 74 Cohort B (prior treatment): 65 |
39 (2 CR, 27 PR) 31 (0 CR, 20 PR) |
6.3 mo (A) and 4.5 mo (B) | 13.1 (A) and 12.9 (B) |
| Mornex et al. 200333 | Fotemustine + WBRT | 37.5 Gy in 15 fractions | III | 37 | 10 | – | 2.9 (NS) |
| Margolin et al. 20124 | Ipilimumab | None | II | Cohort A (without corticosteroids): 51 Cohort B (with corticosteroids): 21 |
10 (5 PR) 5 (1 PR) |
– | 7 (A) and 4 (B) |
| NIBIT-M1 Di Giacomo et al. 201234 |
Ipilimumab + fotemustine | None | II | 20 with asymptomatic brain mets | 40 (2 irCR, 6 irPR) | – | – |
| Agarwala et al. 200414 | Temozolomide | None | II | 117 | 7 (1 CR, 7 PR) | 1.2 mo | 3.2 |
| Hwu et al. 200535 | Temozolomide + thalidomide | None | II | 15 | 12 (2 CR, 1 PR) | – | 5 |
| Atkins et al. 200836 | Temozolomide + thalidomide + WBRT | 30 Gy in 10 fractions | II | 39 | 7.6 (1 CR, 2 PR) | 1.8 mo | 4 |
| Margolin et al. 200237 | Temozolomide + WBRT | 30 Gy in 10 fractions | I/II | 31 | 9.7 (1 CR, 2 PR) | 2 mo | 6 |
irCR, immune-related complete response; irPR, immune-related partial response; CR, complete response; PR, partial response; (NS), not significant; WBRT, whole brain radiotherapy.